Anyone have any thoughts on the recent rise in price?

It just keeps going up up up +4p today anyone have any news/thoughts on this stock

Nice rise again on the back of news up 34p now 237.

Obviously good news all round. A stark contrast to earlier times; but it looks like the Business has somewhere to go and regular sales to tide them over until new technologies are brought to market. The only worry still is the PE ratio, but I guess further sales will reduce this, soon enough.

January 27, 2005 09:21 AM US Eastern Timezone

BioSource Releases First Protein Microarray to Quantify Specific Phosphorylation of Proteins

CAMARILLO, Calif.--(BUSINESS WIRE)--Jan. 27, 2005--BioSource International, Inc. (Nasdaq:BIOI), today announced that it has commercialized the first multiplex protein microarray able to quantifiably and reproducibly measure multiple phosphorylated proteins in one sample, the Mercator(TM) PhosphoArray. Through collaboration with Whatman(R) Schleicher & Schuell(R), BioSource has produced a novel assay capable of altering the methods whereby scientists can study protein phosphorylation for the research of disease.


Whatman Schleicher & Schuell is a leader in protein array technology beginning with the development of the FAST Slide, the premier protein arraying surface. The nitrocellulose surface, combined with BioSource's extensive experience in Signal Transduction assay development, has led to a highly sensitive, rapid and reproducible assay that simultaneously quantifies 10 phosphoproteins. BioSource will offer a scanning service allowing any researcher to use the array without the barrier of instrumentation.

"Mercator(TM) PhosphoArrays provide a wealth of information about a signaling system from one of the most innovative technologies on the market," said Terrance Bieker, BioSource's President and Chief Executive Officer. "The information resulting from the application of this technology should provide scientists with important data on cell systems across multiple pathways, giving insight into disease states," Mr. Bieker continued.

Dr. Robert Negm, Director, Business Development of Whatman Schleicher & Schuell stated, "We are very pleased with this product resulting from our partnership with BioSource, as it will substantially increase the number of cell-signaling scientists who may benefit from combining our focus in protein microarray technology with BioSource's strengths in developing market-leading immunoassay reagents."

This multiplex protein microarray product is the first of what is intended to be a broad line of BioSource protein microarrays capable of targeting disease research in oncology, neurobiology and inflammation. The product enhances BioSource's position as a market leader in providing quantitative Signal Transduction phosphoELISAs(TM).

About BioSource International, Inc.

BioSource International, Inc. is a broad-based life sciences company focused on providing integrated solutions in the areas of functional genomics, proteomics, and drug discovery through the development, manufacturing, marketing, and distribution of unique, biologically active reagent systems which facilitate, enable, and accelerate pharmaceutical development and biomedical research. For more information, please visit the Company's Web site at www.biosource.com.

About Whatman

Whatman (WHM.L) is a global leader in separations technology and is known in the scientific community for providing innovative life science products and solutions. With the recent acquisition of Schleicher & Schuell, Whatman offers a more comprehensive product range to its customers worldwide and enters the proteomics market with S&S's core competency in protein chip technologies. For more information visit us at www.whatman.com

Statements included in this release that are not historical facts may be considered forward-looking statements that are subject to a variety of risks and uncertainties. In addition, readers are urged to consider statements that include the terms "believes," "belief," "expects," "plans," "objectives," "anticipates," "intends," "targets," "projections," or the like to be uncertain and forward looking. For these statements, we claim the safe harbor for "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Factors that could cause actual results to differ and vary materially from expectations include, but are not limited to, our ability to expand our product offerings and any transition to new products, product quality and availability, any change in business conditions, changes in our sales strategy and product development plans, competitive pricing pressures, continued market acceptance of our products, name recognition of our products, delays in the development of new technology, possible invalidity or infringement issues related to intellectual property or proprietary rights, changes in customer buying patterns, one-time events, and other important factors disclosed previously and from time to time in our filings with the Securities and Exchange Commission. These factors should not be construed as exhaustive or as any admission regarding the adequacy of disclosures made by us. We cannot always predict or determine what factors would cause actual results to differ materially from those indicated by forward-looking statements or other statements. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Whatman profit hit by accounting error
MoneyAM
Life sciences company Whatman said its full-year earnings before interest, tax and amortisation are expected to be slightly lower than current market expectations.

The company said somewhat slower sales growth will affect its operating margins.

The company's profits for the year will be adversely affected by 600,000 due to the discovery of an accounting error in the recording of stock in its US operations, Whatman said in a trading statement.

The company narrowed its full-year revenue growth forecast range to 6-7 pct from the previous 6%-8%.

Revenues during the first half increased 8% compared to the same period in 2005, excluding the effect of exchange rate movements, it said.

'In the second half, we have seen an overall softening in the market and it has taken longer than anticipated to rebuild customer volumes following the disruption resulting from the restructuring of our manufacturing facilities last year,' Whatman added

Is it time to buy?